Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

China's first multivalent vaccine to provide enhanced protection against COVID variants
Published on: 2023-02-16
Share to
User Rating: / 0
PoorBest 

Beijing has begun inoculating China's first multivalent vaccine that can provide broad spectrum protection against COVID variants, developed by Chinese vaccine producer Sinocelltech with clinical research data showing that it has the advantages in safety and immunity persistence.

At the beginning of December 2022, Sinocelltech's COVID recombinant protein bivalent vaccine was approved for emergency use, and has since been recommended by the country's second booster for enhanced immunization plan, according to media reports.

Sinocelltech's clinical trials both at home and abroad have demonstrated that the vaccine is highly effective against existing omicron strains BA.1 and BA.5, and has the potential to work against future variants too, the firm was quoted as saying in previous media reports.

Some hospitals in Beijing have already received the vaccine, for example, in Yizhuang area, southeast suburb of the capital city, local residents can be inoculated with Sinocelltech's bivalent vaccine, in addition to the previous four types of COVID vaccines.

北京开始接种国内首个针对新冠变异株广谱多价疫苗

据北京日报,神州细胞公司对外披露,由其研发的新冠重组蛋白二价疫苗近日正式在北京开始接种。这是国内首个针对变异株的新冠广谱多价疫苗,临床研究数据显示,具有安全性和免疫持久性优势。2022年12月初,神州细胞的新冠重组蛋白2价疫苗安诺能获批紧急使用,此后也获得《新冠病毒疫苗第二剂次加强免疫接种实施方案》推荐。神州细胞相关负责人对外介绍,目前安诺能已经发货,陆续抵达北京各区县和接种单位,符合接种条件的市民可以咨询附近接种点,预约接种。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.